Physician profile
Teddy E Webb
NPI 1508890666
$14,750.77
in general payments reported to CMS, 2019-2025
58 companies · $1,741 in 2025
The $1,741 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,087 · 2020: $1,879 · 2021: $3,238 · 2022: $2,103 · 2023: $1,927 · 2024: $1,776 · 2025: $1,741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,350 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,350.25 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,412.50 | 2019-2025 | Linzess, Viberzi, Vraylar |
| Novo Nordisk INC | $1,317.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,311.64 | 2019-2025 | |
| Glaxosmithkline, LLC. | $999.15 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $979.75 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $851.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $820.35 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $743.47 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $627.72 | 2019-2022 | |
| Abbott Laboratories | $524.08 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $500.76 | 2019-2024 | Evenity, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $467.84 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $438.65 | 2019-2023 | Belsomra, Steglatro, Januvia |
| Janssen Pharmaceuticals, INC | $342.71 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $314.07 | 2019-2024 | Trintellix |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teddy Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.